Eden Health International
Eden Health International, LLC, doing business as Eden, is a United States-based Telehealth company focusing on metabolic health. Eden was founded in 2023 by Adam McBride, CEO, and Josh Khan, President. The company provides personal care products, prescription medications, over-the-counter medications, and dietary supplements.
Using a direct-to-consumer model, Eden connects users to independent licensed medical providers for virtual medical consultations through the company's digital platform.[1] Medications are shipped directly to the consumer by state-licensed pharmacies if prescribed.
Products and Services
Eden offers metabolic health medications, such as semaglutide and tirzepatide, and compounded prescription medications.[2][3][4][5] In addition to its metabolic health offerings, Eden provides treatment programs for hair loss, perimenopause/menopause hormone therapy, and wellness-focused therapies such as NAD+, sermorelin, and other dietary supplements.[6]
Eden opened its first health club in Greenwood Village, CO.[7] Eden Health Club offers wellness services, such as personal training, hormone replacement therapy, red light therapy, injectables, and prescription drugs.
Eden acquired Contigo Compounding Pharmacy, a 503A compounding pharmacy in Albuquerque, New Mexico, in August 2025.[8] Compounding pharmacies provide personalized medication tailored to the needs of each individual patient.[3][9][10] Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before reaching patients.[11]
References
This article "Eden Health International" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Eden Health International. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- ↑ Dolphin, Natalie. "Branding Best Practices: Tips For Telehealth Weight Loss Companies". Forbes. Archived from the original on 2025-04-06. Retrieved 2026-01-13.
- ↑ Research, Center for Drug Evaluation and (2025-09-25). "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss". FDA.
- ↑ 3.0 3.1 Reports, Staff (2025-02-11). "Goodbye Needles, Hello Convenience: Exploring Compounded Semaglutide". The Astorian. Retrieved 2026-01-13.
- ↑ Sokary, Sara; Bawadi, Hiba (2025-06). "Exploring beyond numeric weight loss: The metabolic effects of semaglutide". Clinical nutrition ESPEN. 67: 435–440. doi:10.1016/j.clnesp.2025.03.010. ISSN 2405-4577. PMID 40107359 Check
|pmid=value (help). Check date values in:|date=(help) - ↑ Jastreboff, Ania M.; Aronne, Louis J.; Ahmad, Nadia N.; Wharton, Sean; Connery, Lisa; Alves, Breno; Kiyosue, Arihiro; Zhang, Shuyu; Liu, Bing; Bunck, Mathijs C.; Stefanski, Adam (2022-07-20). "Tirzepatide Once Weekly for the Treatment of Obesity". New England Journal of Medicine. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. ISSN 0028-4793.
- ↑ reports, Staff (2025-06-03). "Eden's NAD⁺ Program Sparks New Conversations on Aging and Longevity". Columbia County Spotlight. Retrieved 2026-01-13.
- ↑ Rehfeldt, Courtney (2025-02-19). "Eden Moves Beyond Telehealth With 'Sanctuary of Wellness' Club". Athletech News. Retrieved 2026-01-13.
- ↑ "Eden Health Acquires Contigo Compounding | Mergr". mergr.com. Retrieved 2026-01-13.
- ↑ "Eden Health Strengthens Personalized Care by Acquiring Contigo - Investors Hangout". investorshangout.com. Retrieved 2026-01-13.
- ↑ "What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained". Yahoo Life. 2025-02-10. Retrieved 2026-01-13.
- ↑ Research, Center for Drug Evaluation and (2025-09-16). "Compounding and the FDA: Questions and Answers". FDA.
